Quick Answer
ACRO BIOMEDICAL CO., LTD. reported Total Revenue of $0.00 for fiscal year 2025.
ACRO BIOMEDICAL CO., LTD. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 -100.0% |
$658.5K -45.0% |
$1.20M | — |
| Net Income | -$101.1K -139.1% |
-$42.3K +99.5% |
-$8.81M +44.5% |
-$15.87M -106.2% |
-$7.70M -6454.0% |
-$117.5K +68.3% |
| Diluted EPS | $0.00 | $0.00 +100.0% |
-$0.15 +42.3% |
-$0.26 | — | — |
| Total Assets | $14.1K -55.9% |
$32.0K -45.3% |
$58.5K -91.5% |
$687.5K -9.7% |
$761.1K -23.7% |
$998.1K -6.7% |
| Cash and Equivalents | — | — | — | — | — | $18.1K +1131.2% |
| Stockholders Equity | -$387.0K -31.2% |
-$295.0K -14.8% |
-$257.0K -152.8% |
$486.4K -24.4% |
$643.7K -6.1% |
$685.9K -21.5% |
| R&D Expense | — | $0.00 -100.0% |
$4.79M -52.4% |
$10.08M +90.7% |
$5.29M | — |
| Operating Income | -$154.0K -305.8% |
-$38.0K +99.6% |
-$8.80M +44.5% |
-$15.87M -106.3% |
-$7.69M -5797.1% |
-$130.5K +70.5% |
| Gross Profit | — | — | $0.00 -100.0% |
$140.5K -45.9% |
$259.5K +62.8% |
$159.4K +17.7% |
| Shares Outstanding | 60.04M +0.0% |
60.04M +0.0% |
60.04M +0.0% |
60.04M +0.0% |
60.04M +25.7% |
47.76M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$117.8K | -1051.7% | -657.0% |
| Diluted EPS | September 30, 2025 | $0.00 | — | — |
| Total Assets | September 30, 2025 | $4.3K | -88.8% | -91.9% |
| Cash and Equivalents | June 30, 2021 | $215.5K | +56460.1% | +784.7% |
| Stockholders Equity | September 30, 2025 | -$432.6K | -51.5% | -36.2% |
| R&D Expense | September 30, 2024 | $0.00 | -100.0% | — |
| Operating Income | September 30, 2025 | -$115.1K | -1164.0% | -745.4% |
| Gross Profit | September 30, 2023 | $0.00 | — | — |
| Shares Outstanding | September 30, 2025 | 60.04M | +0.0% | +0.0% |
- ACRO BIOMEDICAL CO., LTD. reported Total Revenue of $0.00 for fiscal year 2025.
- ACRO BIOMEDICAL CO., LTD. reported Net Income of -$101.1 thousand for fiscal year 2025.
- ACRO BIOMEDICAL CO., LTD. showed a decrease of -139.1% in Net Income compared to the prior fiscal year.
- ACRO BIOMEDICAL CO., LTD. reported Diluted EPS of $0.00 per share for fiscal year 2025.
- ACRO BIOMEDICAL CO., LTD. reported Total Assets of $14.1 thousand for fiscal year 2025.
- ACRO BIOMEDICAL CO., LTD. showed a decrease of -55.9% in Total Assets compared to the prior fiscal year.
- ACRO BIOMEDICAL CO., LTD. reported Cash and Equivalents of $18.1 thousand for fiscal year 2020.
- ACRO BIOMEDICAL CO., LTD. showed an increase of +1889.4% in Cash and Equivalents compared to the prior fiscal year.
- ACRO BIOMEDICAL CO., LTD. reported Stockholders Equity of -$387.0 thousand for fiscal year 2025.
- ACRO BIOMEDICAL CO., LTD. showed a decrease of -31.2% in Stockholders Equity compared to the prior fiscal year.
- ACRO BIOMEDICAL CO., LTD. reported R&D Expense of $0.00 for fiscal year 2024.
- ACRO BIOMEDICAL CO., LTD. showed a decrease of -100.0% in R&D Expense compared to the prior fiscal year.
- ACRO BIOMEDICAL CO., LTD. reported Operating Income of -$154.0 thousand for fiscal year 2025.
- ACRO BIOMEDICAL CO., LTD. showed a decrease of -305.8% in Operating Income compared to the prior fiscal year.
- ACRO BIOMEDICAL CO., LTD. reported Gross Profit of $0.00 for fiscal year 2023.
- ACRO BIOMEDICAL CO., LTD. showed a decrease of -100.0% in Gross Profit compared to the prior fiscal year.
- ACRO BIOMEDICAL CO., LTD. reported Shares Outstanding of 60.04 million shares for fiscal year 2025.
- ACRO BIOMEDICAL CO., LTD. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: